Compare Ascendis Pharma A/S (ASND) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Infosys Limited — how do they compare? Ascendis Pharma A/S trades at $253.09 (market cap $16.67B), while Infosys Limited trades at $12.24 (market cap $50.55B). The key difference: Infosys Limited is far larger — about 3× Ascendis Pharma A/S's market cap, and Infosys Limited pays a 4.16% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | INFY | |
|---|---|---|
Market Cap | $16.67B | $50.55B |
Sector | Health | Technology |
52-Week High | $277.18 | $20.22 |
52-Week Low | $189.74 | $10.49 |
Enterprise Value | $17.04B | $48.30B |
Dividend Yield | — | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
INFY trades at $12.17, down 3.11% today, with mixed technical signals: a bullish moving average trend but overbought RSI levels. The company reported a Q2 2026 EPS miss but beat in prior quarters, maintaining strong profitability with a 16.37% net margin. Recent news highlights AI collaborations and a CEO transition, while institutional activity shows both buying and selling.
Outlook is cautious due to near-term revenue softness and lowered growth guidance, though solid cash flow and margins provide support. Risks include competitive pressures and macroeconomic headwinds. Analysts are mixed with a consensus price target of $11.05, suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
